Rodrigo Refoios Camejo

Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial

Vincent Meininger, Angela Genge, Leonard H van den Berg et al. · The Lancet Neurology · 2017 · 82 citations · Full text

Amyotrophic Lateral Sclerosis, Neurological Disorder, Clinical Neurology +4

The ASCEND-NHQ randomized trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis chronic kidney disease

Kirsten L. Johansen, Alexander R. Cobitz, Ajay Singh et al. · Kidney International · 2023 · 35 citations · Full text

Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling Era

Borut Čižman, Helen T. Smith, Rodrigo Refoios Camejo et al. · Kidney Medicine · 2020 · 32 citations · Full text

Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Naive and Treatment-Experienced Patients in Canada

Nicolas Despiégel, Delphine Anger, Monique Martin et al. · Infectious Diseases and Therapy · 2015 · 22 citations · Full text

A dynamic perspective on pharmaceutical competition, drug development and cost effectiveness

Rodrigo Refoios Camejo, Clare McGrath, Ron M. C. Herings · Health Policy · 2010 · 20 citations

Economics, Pharmaceutical Innovation, Health Economics +11